ClinicalTrials.gg
RecruitingNCT07552233Updated Apr 27, 2026

NK Cell Therapy for Malignant Solid Brain Tumors

An interventional study of Autologous NK cells in Malignant Solid Brain Tumors, Glioblastoma (GBM) and Glioblastoma Multiforme (GBM), sponsored by Peking University Third Hospital. Recruiting at 4 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Peking University Third Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 143 studies in Glioblastoma with a site in China — 74 open to participants now, 81 under way, 7 of them phase 3. Glioblastoma · China.

Planned enrollment
85th of 128
27 · median 36
Started
2026
with 20 others
No phase
13 of 143
8 open now
Primary completion
2030-12
later than 78 of 80 live
Registered
130th of 143
by date

Among the 143 studies in Glioblastoma with a site in China, this one is the 85th largest by planned enrollment of the 128 interventional ones that give a count, is one of 21 that started in 2026, is one of 13 with no phase, reaches primary completion later than 78 of the 80 other live ones, and was the 130th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

74 of the 143 studies in Glioblastoma with a site in China are open now. Recruiting first, the newest first:

68 more — sign in →

All 74 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Glioblastoma with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, open-label investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, and feasibility of combined intracranial and intravenous administration of ex vivo expanded and activated natural killer (NK) cells in adult patients with malignant solid brain tumors who have failed standard treatment modalities. The primary objective is to determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of the combined NK cell therapy. Secondary objectives include preliminary assessment of anti-tumor activity as measured by progression-free survival (PFS), overall survival (OS), objective response rate (ORR) per RANO criteria, and evaluation of the immunological effects of NK cell infusion in the tumor microenvironment and peripheral blood.

03

Conditions studied

  • Malignant Solid Brain Tumors
  • Glioblastoma (GBM)
  • Glioblastoma Multiforme (GBM)
  • Brain Metastasis
  • Malignant Meningioma

Keywords

  • Malignant Solid Brain Tumors
  • Immunotherapy
  • Natural Killer Cell
  • NK Cell
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age 18-70 years old (both ends included)
  2. At least one evaluable lesion with previous or pathohistologic confirmation of malignant central nervous system tumor, with imaging suggestive of continued progression or recurrence after comprehensive treatment
  3. Performance Status (KPS) ≥ 60%
  4. > 4 weeks, and must be able to undergo an MRI with contrast
  5. Patients who completed radiotherapy or systemic therapies (including temozolomide/bevacizumab or other agents) for at least 4 weeks prior to enrollment. All prior treatment-related toxicities should be defined as ≤ grade 1 (except for toxicities such as alopecia or leukoplakia) according to the Common Terminology Standard for Adverse Events ( 6.0)
  6. Dexamethasone dose ≤ 4 mg/day or equivalent dose, or no dexamethasone administered
  7. Must have adequate organ and marrow function as defined below:

    • White blood cell count (WBC) ≥ 3 x 10\^9/L
    • (ANC) > 1 x 10\^9/L
    • (Hb) ≥ 90 g/L
    • (PLT) ≥ 80×10\^9/L
    • Albumin transaminase () \& albumin transaminase (AST) \< 1.5 × institutional (ULN)
    • Serum creatinine (Cr) \< 1.5 x institutional ULN
    • Total \< 1.5 x institutional ULN
    • PT \& ≤ 1.25 x institutional ULN
  8. No obvious hereditary diseases
  9. Normal cardiac function with >55%
  10. No bleeding and coagulation disorders
  11. Absence of positive blood cultures for bacteria, fungus, or virus within 48-hours prior to NK cell infusion and/or there aren't any indications of meningitis
  12. Fertile women must have had a pregnancy test with a negative result within 7 days prior to the start of treatment, and subjects are willing to use (hormonal or barrier method of birth control or abstinence) during the clinical trial and for 6 months after the last cell infusion; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
  13. Signed, written

Exclusion criteria

Exclusion Criteria:

  1. Active or C virus, infection, or other untreated active infection
  2. Pregnant and lactating women
  3. Participants with organ failure
  4. Participants with a chronic disease requiring immunologic or hormonal therapy
  5. Participants with an allergy to immunotherapy and related cells
  6. Participants with uncontrolled intercurrent illness
  7. Participants with psychiatric illness/social situations that would limit compliance with study requirements
  8. Participants with a history of organ transplantation or who are awaiting organ transplantation
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Low dose

    Intracranial/Intrathecal Injection: 1x10\^8 NK cells, every 2 weeks Intravenous Infusion: 2x10\^8 NK cells, every 2 weeks

    Drug: Autologous NK cells

  • Experimental
    Medium dose

    Intracranial/Intrathecal Injection: 1x10\^8 NK cells, every 2 weeks Intravenous Infusion: 9x10\^8 NK cells, every 2 weeks

    Drug: Autologous NK cells

  • Experimental
    High dose

    Intracranial/Intrathecal Injection: 1x10\^8 NK cells, every 2 weeks Intravenous Infusion: 2.9x10\^9 NK cells, every 2 weeks

    Drug: Autologous NK cells

Interventions

  • DrugAutologous NK cells

    Intrathecal Administration Combined with Intravenous Infusion of Autologous NK Cells 1. Intracranial/Intrathecal Injection: NK cells are administered into the cerebrospinal fluid via a surgically implanted intracranial Ommaya reservoir or lumbar puncture. This approach successfully bypasses the blood-brain barrier, allowing NK cells to act directly on tumor lesions in the central nervous system. 2. Intravenous Infusion: Following intracranial/intrathecal injection, the patient receives an intravenous infusion of NK cells.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Defined as the incidence of ≥ Grade 3-4 adverse events related to NK cells according to common terminology criteria for adverse events (CTCAE) v6.0.

    Time frame: 3 months following NK cells administration

  2. Incidence of Dose-Limiting Toxicities (DLTs)

    Defined as events attributable to NK cells infusion within 28 days post-infusion. Grade 3 or higher cytokine release syndrome (CRS) lasting more than 2 weeks, according to American Society for Transplantation and Cellular Therapy (ASTCT) criteria; Any NK cells-related AE requiring intubation; Grade 4 non-hematologic toxicities.

    Time frame: 28 days following initial treatment with NK cells

Secondary outcomes

  1. Objective Response Rate (ORR)

    According to modified RANO criteria, ORR is defined as proportion of subjects with confirmed CR and PR.

    Time frame: 3 months following NK cells administration

  2. Duration of response (DOR)

    According to modified RANO criteria, DOR is defined as time from the date when a response of confirmed CR/PR is first met to the date of confirmed disease progression or death.

    Time frame: 3 months following NK cells administration

07

Study locations

3 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2030, 56 months later.

Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 56 months is close to that.

Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
Apr 27, 2026
StartEst.
Apr 2026
Primary completionEst.
Dec 2030
CompletionEst.
Dec 31, 2030
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07552233
Collaborators
Henan Academy of Innovations in Medical Science, Zhengzhou Second Hospital, Qinhuangdao Runze Hospital
Responsible party
Chenlong YANG (Professor, Peking University Third Hospital) — Principal investigator
First posted
Apr 27, 2026
Start date
Apr 2026 (estimated)
Primary completion
Dec 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Apr 27, 2026

Study contacts

Chenlong YANG, M.D., Ph.D.
Contact
vik.yang@pku.edu.cn
(+86)-135-1108-7060

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion